AbbVie Inc. (ABBV) — closed signal from October 7, 2025
Partial Published before the outcome was known, scored automatically when the window closed on January 5, 2026.
Predicted vs. what happened
What happened
Reached 39% of the predicted growth at its peak, without hitting the target.
The thesis — published October 7, 2025
AbbVie mixes steady cash from its medicines with signs the price could rebound over the next three months. Lots more people are buying than usual, and it was recognized for a strong dividend that appeals to income-focused investors. Newer drugs Skyrizi and Rinvoq keep gaining, supporting the story. In a gently rising market, this lower volatility stock could climb as we watch policy shifts and competition.
Primary drivers
- Price looks washed out and buyers are stepping in more than usual
- Long record of raising dividends can attract investors seeking income
- Strong sales from Skyrizi and Rinvoq are key engines for future growth
- Tends to move less than the market, offering steadier participation
How it played out
ABBV: target was not reached
Lyra published ABBV at 228.54 on 2025-10-07 for a short-term window ending 2026-01-05. The thesis expected 12% growth to 254.13. It pointed to a washed-out price, heavier-than-usual buying, a long dividend record, growth from Skyrizi and Rinvoq, and steadier participation in a gently rising market.
Inside the window, ABBV rose to 239.29 on 2025-11-13, a 4.7% peak gain. That was still below the target. It never got there. By 2026-01-05, the stock ended at 220.18. The thesis partially played out early, then missed the published target.
What happened during the window
On October 31, 2025, Investors.com reported that AbbVie posted third-quarter revenue of $15.78 billion and adjusted earnings of $1.86 per share. The same report said Skyrizi sales were $4.71 billion and Rinvoq sales were $2.18 billion.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.